
Roman M Chabanon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/199396/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer. Journal of Clinical Investigation, 2019, 129, 1211-1228.	8.2	222
2	Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Clinical Cancer Research, 2016, 22, 4309-4321.	7.0	182
3	Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nature Reviews Cancer, 2021, 21, 701-717.	28.4	150
4	Enduring epigenetic landmarks define the cancer microenvironment. Genome Research, 2018, 28, 625-638.	5.5	74
5	PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer. Cancer Research, 2021, 81, 2888-2902.	0.9	66
6	Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers. Seminars in Cancer Biology, 2020, 61, 180-198.	9.6	28
7	DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. Journal of Clinical Investigation, 2018, 128, 1671-1687.	8.2	19
8	Beyond DNA repair: the novel immunological potential of PARP inhibitors. Molecular and Cellular Oncology, 2019, 6, 1-4.	0.7	18
9	BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer. Journal of Clinical Investigation, 2022, 132, .	8.2	11
10	Understanding genetic determinants of resistance to immune checkpoint blockers. Seminars in Cancer Biology, 2020, 65, 123-139.	9.6	9
11	A Novel Synthetic Lethal Approach to Target <i>MYC</i> -Driven Cancers. Cancer Research, 2022, 82, 969-971	0.9	3